Biotron Ltd Total Liabilities
Biotron Ltd total liabilities. Based on the latest financial reports, Biotron Ltd (BIT) has total liabilities worth AU$817.93K AUD (≈ $578.74K USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Biotron Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biotron Ltd (2000–2026)
Total liabilities of Biotron Ltd from 2000 to 2026. This chart illustrates how Biotron Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore BIT long-term investment intensity to see how much of total assets are deployed in long-term investments.
Biotron Ltd Competitors by Total Liabilities
The table below lists competitors of Biotron Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Divio Technologies AB Series B
ST:DIVIO-B
|
Sweden | Skr29.57 Million |
|
Epwin Group PLC
LSE:EPWN
|
UK | GBX193.00 Million |
|
Purple Biotech
NASDAQ:PPBT
|
USA | $1.95 Million |
|
Diadrom Holding AB
ST:DIAH
|
Sweden | Skr10.12 Million |
|
HeartCore Enterprises Inc
NASDAQ:HTCR
|
USA | $3.80 Million |
|
Ganga Forging Limited
NSE:GANGAFORGE
|
India | Rs302.43 Million |
|
CAP-EX IRON ORE
F:X0V
|
Germany | €146.95K |
Liability Composition Analysis (2000–2026)
This chart breaks down Biotron Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Biotron Ltd (BIT) total assets.
Liquidity & Leverage Metrics
Biotron Ltd Total Liabilities Ratios Explained
Biotron Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biotron Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biotron Ltd (2000–2026)
The table below shows the annual total liabilities of Biotron Ltd from 2000 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | AU$817.93K ≈ $578.74K |
+90.88% |
| 2025-06-30 | AU$428.51K ≈ $303.20K |
-41.90% |
| 2024-06-30 | AU$737.51K ≈ $521.83K |
-23.38% |
| 2023-06-30 | AU$962.49K ≈ $681.03K |
+18.31% |
| 2022-06-30 | AU$813.57K ≈ $575.65K |
+75.52% |
| 2021-06-30 | AU$463.51K ≈ $327.96K |
-45.67% |
| 2020-06-30 | AU$853.19K ≈ $603.69K |
+104.11% |
| 2019-06-30 | AU$418.00K ≈ $295.76K |
+23.78% |
| 2018-06-30 | AU$337.70K ≈ $238.95K |
-45.49% |
| 2017-06-30 | AU$619.51K ≈ $438.34K |
+78.89% |
| 2016-06-30 | AU$346.32K ≈ $245.04K |
-26.81% |
| 2015-06-30 | AU$473.18K ≈ $334.80K |
-0.31% |
| 2014-06-30 | AU$474.64K ≈ $335.84K |
+21.37% |
| 2013-06-30 | AU$391.08K ≈ $276.71K |
+103.50% |
| 2012-06-30 | AU$192.18K ≈ $135.98K |
-21.34% |
| 2011-06-30 | AU$244.32K ≈ $172.87K |
+74.16% |
| 2010-06-30 | AU$140.29K ≈ $99.26K |
-36.90% |
| 2009-06-30 | AU$222.33K ≈ $157.31K |
-47.56% |
| 2008-06-30 | AU$423.94K ≈ $299.97K |
+160.05% |
| 2007-06-30 | AU$163.02K ≈ $115.35K |
-48.75% |
| 2006-06-30 | AU$318.11K ≈ $225.08K |
+112.24% |
| 2005-06-30 | AU$149.88K ≈ $106.05K |
-2.25% |
| 2004-06-30 | AU$153.33K ≈ $108.49K |
+3.55% |
| 2003-06-30 | AU$148.08K ≈ $104.77K |
+3.63% |
| 2002-06-30 | AU$142.90K ≈ $101.11K |
+28.22% |
| 2001-06-30 | AU$111.45K ≈ $78.86K |
+406.59% |
| 2000-06-30 | AU$22.00K ≈ $15.57K |
-- |
About Biotron Ltd
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops pre… Read more